1

BIO issues glowing report on US Bioscience Industry

I’ll be posting more soon about the 2018 Biotechnology Innovation Organization’s  International Convention, where I spent the day on Monday, but thought the following press release might be of interest.  Despite the glowing industry review,  many sessions dealt with difficulties the industry is facing. The release follows.

–Anita M. Harris

A study released on June 5  at the BIO International Convention in Boston shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.

The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain.

For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.

“This report highlights the enormous economic impact delivered by our industry. This strong performance is due to the vital and wide-ranging collaborations between industry partners, universities, and policymakers that provides a business climate that supports the development of innovative bioscience products and high paying jobs,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization.”

The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds it advancing with positive results. The U.S. is experiencing strong gains in bioscience venture capital funding, growth in patents, a recent ramp-up in bioscience-related university R&D expenditures and increasing research funding from the National Institutes of Health (NIH).

“The bioscience industry is vital to the U.S. not only as an innovation engine that is improving lives, but also as a major economic driver that is consistently generating high-quality jobs and significant economic output across the nation,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.

The state-by-state industry assessment is the eighth in a biennial series, developed in partnership by TEConomy and BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.

Additional highlights from the industry economic analysis include:

  • The industry is a major economic driver and is well distributed across U.S. states and cities:
    • 41 states experienced net job growth in the biosciences between 2014-2016
    • 38 states and Puerto Rico have an employment specialization in at least one bioscience subsector
    • 213 of 383 U.S. metropolitan areas have at least one bioscience specialization

Highlights from the analysis of the innovation ecosystem for the bioscience industry include:

  • Strength in recent venture capital and patenting trends:
    • Venture capital investments have reached new highs. More than $66 billion in venture capital was invested in bioscience companies during the 2014 through 2017 period, including a new annual high in 2017 at $20 billion invested.
    • Innovation continues to drive the biosciences, since 2014 the U.S. has increased patent totals in bioscience-related technology classes by nearly 5 percent, or 1.6 percent per year, on average. 2017 had a total of nearly 27,000 patents awarded to U.S. inventors, another new high.
  • Growth for academic biosciences R&D in 2016
    • After several years of concerns raised about the declining and/or flat NIH research budgets and the subsequent effects on academic and other research, NIH funding is back on the rise. There have been budget increases sustained each of the last three years.
    • Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has increased. Following a 1.5 percent decline in 2015, academic R&D expenditures in the biosciences increased 5.5 percent to $42 billion in 2016.

The TEConomy/BIO report includes individual profiles for all 50 states, the District of Columbia and Puerto Rico, and can be found on the BIO website at bio.org/jobs2018.

About BIO
BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO’s blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

About TEConomy
TEConomy Partners, LLC is a global leader in research, analysis, and strategy for innovation-based economic development. Today we’re helping nations, states, regions, universities, and industries blueprint their future and translate knowledge into prosperity. The Principals of TEConomy Partners include the authors of the prior Battelle/BIO State Bioscience Development reports, published since 2004. For more information, please visit http://www.teconomypartners.com.




BIO-IT World 2018 awards top innovators at Boston Conference-Expo

Spent an interesting Wednesday afternoon, last week,  visiting exhibitors at the Bio-IT World Conference & Expo –several of whom won “Best of Show” Awards later that day.

The judges, listed below,  named winners in six categories: Data Integration & Management; Analysis & Data Computing; Genomic Data Services; Data Visualization & Exploration; Storage Infrastructure & Hardware; and the Judges’ Prize.  Attendees also voted on the People’s Choice Award, selecting products that they believed measurably improve workflow or capacity, enabling better research.

One of my favorites was Nanome, which won best in show for Data Visualization and Exploration.
Nanome uses virtual reality to improve the drug discovery process, according to its award application. The company offers applications for experimentation, collaborattion, and learning at the nano-scale– leveraging  VR hardware such as the Oculus Rift and HTC Vive to create immersive virtual workspaces allowing users to visualize, design, and simulate molecules, proteins, and more.

At  Nanom’se i BIO–IT World booth, Marketing Director Jarrell James handed me a pair of VR goggles and two joysticks (?) with which  I could explore within a molecule–by seeming to make components larger, smaller or revolve.

A more sophisticated user might be able to:

  • -Import molecular structures from a local machine or an online database such as RCSB or DrugBank.
  • – Manipulate molecular structures by literally grabbing, rotating, or enlarging the area of interest with their hands.
  • – Apply different representations to their selection of Atoms, Residues, Chains, or Proteins such as Stick, Wire, Ball & Stick, or Van der Waals.
  • – Measure distances and angles between atoms.
  • – Mutate amino acids and cycle through rotamer libraries.
  • – Design small molecules by building with any element from the periodic table.
  • – Minimize manipulated molecules to prevent clashes and provide a local energy minimum conformation.
  • – Duplicate or Split any selected area of your structure to modify or export independently.
  • – Export your molecular structures to PDB.
  • – Join a virtual reality session as a guest with or without virtual reality hardware.
  • – Present and collaborate in the same virtual environment with colleagues to demonstrate proposals or compare before and after results.

Nanome plans next to enter the education space. The company’s VR technology wil help high school and college students , likely already proficient in gaming technology,  better understqand biologic processes, James said.

 

 

The Hyve 

I also spent some time with the folks at Hyve…whose fake robot ( that is, a “robot inhabited” by a human) did make me  curious about Hyve’s work.


RADAR-base
radar-cns.org

As described in the company’s award submission,  the company’s RADAR-base, developed in the framework of the IMI RADAR-CNS project, is an open source platform designed to securely collect, store and share readings from wearable devices and smartphone sensors to enable remote monitoring. The RADAR-base platform consists of three major categories of components:

 

  • Data ingestion: Recognizing and registering data-sources (including smartphones and wearable devices), collecting the data via a direct Bluetooth connection or through a 3rd party API and streaming in near real time to the server (green box in the figure). Using Apache Kafka, the collected data is streamed to dedicated topics in real-time where the data is optimally schematized using Apache Avro;
  • Data storage and management: Consists of two centralized storage systems behind an authorized security layer. A cold-storage based on HDFS that is scalable and fault-tolerant focusing on storing large volumes of high frequency raw-data, and a hot-storage based on MongoDB storing aggregated data to provide a near real-time overview of the raw-data. (blue box in the figure);
  • Data sharing: Visualizing aggregated data in a live dashboard and exporting raw data for further analyses in various formats including AVRO, JSON and CSV (yellow box in the figure).

The platform is highly secured by a centralized management system of users and their authorities, participants, allowed devices and their specifications. RADAR-Base platform is distributed as Docker containers with associated scripts and configuration files to enable easy installation.

 

 

 In addition, I  visited Sinequa, which took the prize in the Analysis & Data Computing category. 

 

 

 

 


Sinequa ES v10
sinequa.com

The Sinequa Cognitive Search and Analytics platform handles all structured and unstructured data sources and uses Natural Language Processing (NLP), statistical analysis and Machine Learning (ML) in order to create an enriched “Logical Data Warehouse” (LDW). This LDW is optimized for performance in delivering rapid responses to users’ information needs. Users can ask questions in their native language or ask that relevant information be “pushed” to them in a timely fashion when it emerges.

More than 180 connectors ready for use “out of the box” make the process of connecting multiple data sources fast and seamless. Company and industry-specific dictionaries and ontologies can be easily integrated, putting specific knowledge “under the hood” of the Sinequa platform, making it an intelligent partner for anyone in search of relevant subject information.

 

Other awards, as descrbed in company literature: :

Genomic Data Services

Diploid
Moon 1.0
diploid.com/moon

Moon is the first software to autonomously diagnose rare diseases from WES/WGS data. By applying AI to the domain of rare disease diagnostics, Moon brings speed and scalability to the genome interpretation process.

The software only requires the patient’s gender, age of onset and his/her symptoms – in addition to the genetic data. Moon then goes from whole genome variant data (VCF) to pinpointing the causal variant in less than 5 minutes.

The software highlights one or a few variants that could explain the patient’s phenotype. For every variant, Moon displays an extensive list of annotations that it mined from the literature, allowing geneticists to easily verify decisions from the AI algorithms. Moon’s speed does not only save a lot of time and money, it also saves lives: Moon has already proven its utility in the NICU at Rady Children’s Hospital (San Diego): https://goo.gl/7TDrQD.

Unfortunately, about 50% of rare disease patients remain undiagnosed, even after whole genome sequencing and expert interpretation. Most hospitals don’t have the resources to keep analyzing negative cases even though new correlations between genes and disorders are published every day. Moon changes all this: as the software autonomously mines the literature and analyses samples, it can reanalyze older, negative cases in the background. Only when new information that might lead to a diagnosis becomes available, the assigned geneticist is notified. That way, hospitals can frequently reanalyze thousands of cases with minimal labor, providing a perspective to undiagnosed patients.

 

Storage Infrastructure & Hardware

PetaGene
PetaSuite Cloud Edition – Version 1.2
petagene.com

Launching at Bio-IT World 2018, PetaSuite Cloud Edition (CE) combines two innovations: (i) the ability for a user’s software tools and pipelines to seamlessly integrate with a wide variety of cloud platforms without modification, and (ii) significantly improved, high-performance, scalable PetaSuite genomic compression technology. 

For example, users can now directly run, without modification, their custom BWA-mem, GATK, Python, Java, shell scripts, and other POSIX-based software/pipelines streaming directly to/from AWS, Google Cloud, Azure, and private cloud storage, as though they were local filestores. PetaSuite CE supports each platform’s object encryption during transfer and at rest. User applications can connect to multiple cloud platforms, buckets and regions as desired, transparently, and on demand, in user-mode, without needing to modify their pipelines, setup mounts, or have administrator privileges.

Whether running on bare-metal, in VMs, or within Docker containers, for public, private or hybrid cloud, PetaSuite CE enables organizations to unlock the power of distributed object storage seamlessly from their POSIX-compliant tools and pipelines.

PetaSuite CE is built from the ground-up for the extremely high performance streaming and random-access workloads demanded by genomics applications. The integrated, transparent PetaGene compression has been significantly improved to deliver even faster compression and greater reductions of up to 6x of both BAM and FASTQ.GZ files, enabling large costs savings in cloud storage and data transfer times. Moreover, PetaGene compression can also preserve the MD5 checksum of the original BAM or FASTQ.GZ file and not just the internal raw SAM/FASTQ data.

 

The Judges’ Prize went to 

 Linguamatics and its iScite 2.0 (iscite.com) provide a Software-as-a-Service search application that puts the power of text analytics directly into scientists’ hands, according to the company writeup.

Using Linguamatics’ Award-winning Natural Language Processing
Researchers can extract and analyze relevant data to rapidly answer business-critical questions. iScite utilizes Linguamatics’ award-winning Natural Language  L(NLP) based blend of analytical methods. By understanding the semantics and structure of text, iScite handles the variety of ways people express the same information, ensuring searches are comprehensive and accurate.

Easy to use on any device
iScite’s intuitive HTML interface includes a simple search box and auto-complete suggestions. The innovative answer-routing engine lets users answer simple or complex questions using puzzle-piece building blocks – simplifying access to powerful queries that extract concepts, relationships, numerical data such as drug dosages, mutations and more.

Get answers to questions, not just documents
Data sources include Linguamatics’ cloud-hosted content. MEDLINE, Clinical Trials.gov, FDA Drug Labels, PubMed Central, and Patent Abstracts are annotated with curated terminologies for diseases, drugs, genes and organizations. Scientists can answer questions such as:

  • What genes are involved in breast cancer?
  • What protocol designs have been used for immuno-oncology trials?
  • What are the adverse events for kinase inhibitors?

Actionable results
Results are presented in structured form, with bar chart facets for dynamic, visual results-filtering, a document viewer that highlights key terms and relationships, and relevant link-outs. Users can curate, save, and export their results.

iScite allows users across drug discovery and development to cut through the vast information landscape and discover the most valuable insights.

 

The People’s Choice award went to 

OnRamp BioInformatics, Inc. and itsROSALIND™ platform:  the first-ever genomics analysis platform specifically designed for life science researchers to  analyze and interpret datasets, while freeing up more time for bioinformaticians.

Named in honor of pioneering researcher Rosalind Franklin, who made a major contribution to the discovery of the double-helix structure of DNA with her famous photograph 51, OnRamp’s ROSALIND platform aims to simplify the practice of genomic data interpretation. According to the company’s writeup,  ROSALIND puts the researcher into the driver’s seat of data analysis and democratizes bioinformatics by broadly expanding access to genomic and proteomic technologies for cancer research, precision medicine and sustainable agriculture.

While many open-source tools remain the lifeline of genomic analysis, a simplified and innovative user experience for the biologist can empower them to run their own analyses, while utilizing these tools without the need for typing any command-line instructions.

ROSALIND is powered in partnership with Google Cloud and features scalable compute power and economical cloud-based storage. ROSALIND is a swarming docker-based genomic analysis solution incorporating the industry’s most trusted open-source tools and algorithms, with an angular front-end and secure RESTful API. ROSALIND is also deployable on-premise.

On Ramp technololgists believe that empowering biologists with “an intuitive and comprehensive platform” to explore their data and collaborate with colleagues and bioinformaticians, they  can help accelerate their industry and the widespread adoption of genomic technologies by dramatically lowering costs, reducing  complexity and, ultimately, focus more on what what to do with results, rather than on how to get to them.

 

In the words of Allison Profitt, BIO-IT World’s editor,” The awards program recognizes the best of the innovative product solutions for the life sciences industry on display at the conference,

“It’s always a treat to explore what’s new in our industry.

” The innovation on display by Bio-IT World exhibitors never disappoints, and we are excited to shine a spotlight on the best life sciences has to offer.”

Judges
“The Best of Show program relies on a panel of expert judges from academia and industry who screen eligible new products and hear presentations from a list of finalists on site. This year our judges considered 46 new products and viewed presentations on site from 18 finalists.”

The 2018 judging panel included Joe Cerro, BostonCIO; Chris Dwan, Bridgeplate; Richard Holland, New Forest Ventures; Eleanor Howe, Diamond Age Data Science; Phillips Kuhl, Cambridge Healthtech Institute; Steve Marshall, Marshall Data Solutions; Michael Miller, Genentech; Art Morales, Analgesic Solutions; Nanguneri Nirmala, Tufts University School of Medicine; Alexander Sherman, Massachusetts General Hospital; Subi Subramanian, Vertex Pharmaceuticals; Bill Van Etten, BioTeam; and Proffitt.

 

–Anita M. Harris
Anita Harris is a science writer based in Cambridge, MA. 
New Cambridge Observer is a publication of the Harris Commmunications Group, also in Cambridge, ma.  




Concord’s new Lacoste-Keane gallery plans global presence; features clay sculptor Jeff Shapiro

http://www.lacostegallery.com/

At the opening of a solo show of work by clay sculptor Jeff Shapiro, Lucy Lacoste and LaiSun Keane announced that they have joined forces to form a new gallery, LACOSTE / KEANE, which will focus on contemporary ceramic art.
The gallery, formerly “Lacoste,”  will remain based at 25 Main St. in Concord, MA, but plans to develop a global presence through a new e-commerce enabled website and social media, according to Lucy Lacoste, who founded and ran the original gallery.
Lacoste and Keane, who have worked together for three years, plan “strong, fresh contemporary art exhibitions while maintaining a studio pottery presence.”
At the opening, Jeff Shapiro described his latest approaches.. After nine years in Japan, where he focused on wood-firing techniques and the “character of clay,” he moved to New York’s Hudson Valley, where for 30 years, he has created sculpture that may have “a sensibility to certain qualities of the Japanese aesthetic,. yet is a departure from both traditional Japanese pots.”  He thinks of his latest work as fine art:  that is, sculpture using clay as his medium.  One new series includes a solid-vertical form in black with a rough textured surface. In some cases, he treats the material like stone, waiting until the clay hardens so that he can carve and chisel it to expose its “inner quality.”  

Other new series include tall narrow vertical pieces–monolithic large blocks;  a “cup” series, in which work is broken and reassembled as
deconstructed vessels; structural “cuboids; ”  and highly textured slabs which are fired in an electric kiln.
This is Shapiro’s fourth solo show at the Lacoste. It runs through May 26.
–Anita M. Harris
Anita Harris is a writer and communications consultant based in Cambridge, MA.
New Cambridge Observer is a publication of the Harris Communications Group, also based in Cambridge.



Can Digital Innovation Transform Health Care? Part III: Apps, Devices & Roadblocks

Links to
Part I Overview, Watson, analytics
Part II digital devices, long term care.
Part III Apps, devices, roadblocks

Behavioral and Population Health; Roadblocks to change

Can mobile apps really improve mental health? Cut the costs of health care? Help professionals track and care for patients? At a day-long conference sponsored  on health systems innovation organized the MIT/Sloan MIT  Initiative for Health Systems Innovation (HSI), experts from a variety of fields attempted to answer those and other questions aimed at furthering a transformation of  the US healthcare system.  Part III of a series about the conference describes apps and devices for behavioral health, personalized and long-distance care. It also discusses new state models to integrate community, health and social systems aimed at tracking and caring for patients and points out that no matter how sophisticated the technology, it is still up to human beings to make it work.

Behavioral Health

Don Mordecai, Kaiser Permanente

Dan Mordecai, MD, National Leader, Mental Health and Wellness at the managed care consortium Kaiser Permanente described:

  • Promising mobile apps aimed at helping people prevent or overcome eating disorders, addiction, or suicide; remain on diets or exercise plans; or connect them with treating providers or coaches.
  • Wearables that can measure how much people move or perform text and voice analysis to help professionals understand who needs care, months or years before it is needed.
  • Predictive analytics to help prevent self-harm

While many of the above technologies have yet to be proven effective, Mordecai said, telehealth technology has been shown to be helpful in supporting and promoting long-distance health care for areas with shortages of medical personnel.  Telehealth may be carried out through videoconferencing, store-and-forward imaging, streaming media, and terrestrial and wireless communication.  

Mordecai also pointed out that with digital advances, “we are moving from individual doctor patient relationships” to a “personalized’” system, which relies increasingly on data, but that “there is a long way to go.”    Mordecai plans to use what he termed “crowd sourcing” to analyze the effectiveness of apps and other new health technologies, based on the electronic health records of Kaiser Permanente’s   nearly 12 million patients.

 

State models and population health
Analysis like that used at Kaiser Permanente is crucial for assessing treatment and cutting costs, but it is more challenging to perform outside of managed care programs, which have access to a vast array of patient records, according to Michael Wilkening, the California Undersecretary for Health and Human Services.  Analysis to records for care funded by government or private insurance is hampered by fragmented  social, health provider and  insurance systems and by legal and technical challenges of sharing patient data among those systems,

The New York State Medicaid director, Jason Helgerson, pointed out that for state Medicaid systems,  which serve mainly low-income populations,  it can be difficult to simply keep track of patients,  much less co-ordinate and evaluate their care or reduce their treatment costs.  As an example, he described a city homeless shelter that serves breakfast and dinner, but not lunch. Hungry residents regularly go to the fire station next door and complain of chest pain; they are taken by ambulance to a hospital emergency room, where they are evaluated, at high cost, given lunch, and then transported back to the homeless shelter in time for dinner.

Medicaid systems in at least several states are working on projects to prevent such situations by better integrating social services with medical and behavioral health care. Some are starting to employ analytics to recommend, monitor and measure the success of treatments, and to pay for performance rather than service.  As a result, Helgerson said, “Medicaid may be in the best position to drive change” in health delivery systems.

Roadblocks to change
Still, as a variety of speakers pointed out, despite the promise of digital innovation, there are many roadblocks to change.   Such roadblocks include: reluctance to replace or augment human decision-making with digital solutions;  complex reimbursement systems  and the need for insurer “buy-in” to pay for new technologies;  disparate stakeholders with different goals;  issues of privacy and security;   the  tendency of legislators and other policymakers to view health problems as individual rather than societal;   failure to address the lack of food and shelter that leads to poor health and expensive repeat hospital visits;  and, last but not least, cost.

In the words of Vocera’s Elizabeth Boehm, regarding systemic change, “it takes more than technology to get it done.“

And, as Restef Levi, of the Sloan School, put it: “Technology is important but…at the end of the day, health is about humans.”

 

LINKS TO:

Part I Overview, Watson, analytics
Part II digital devices, long term care.
Part III Apps, devices, roadblocks

Videotapes and photos of the conference, held November 29, 2017, are available at http://mitsloan.mit.edu/alumni/events/2017-cambridge-health-conference/

–Anita M. Harris

Anita Harris is a writer and communications consultant specializing in health science and technology.

New Cambridge Observer is a publication of the Harris Communications Group, a content and digital marketing firm based in Cambridge, MA.




Art collector to share his vision at Lacoste starting Feb 3, 2018, Concord, MA

Ever wonder why people collect art?

You can find out at “Through the Eyes of a Collector,” an exhibit  opening Saturday, Feb. 3, 2018 and running through Feb. 28 at the Lacoste Gallery, in Concord, Ma.

AshwiniBhat Matrikas

The exhibit offers an insight into the art collecting practices of Steve Alpert, an avid ceramic art lover and collector for more than 40 years, according to  the Lacoste invitation.  Alpert has served on the board  of MFA Boston, as Board Chairman of the Institute for Contemporary Art, and was  founder and Chairman of Rose Art Museum at Brandeis University.

In this show, he  brings together a diverse group of artists whose work ranges from studio pottery to figurative and sculptural ceramic art.

 

 Gaden of Eartlhy DelightsThe artists include:Michael Ashley, Ashwini Bhat, Rick Hirsch, Jeff Kell, Eva Kwong, KyungMin Park and Jack Thompson.

The show, which runs through February 28,  represents Alpert’s vision.  Its goal is to inform new generations of ceramic art fans and collectors on how to begin an astute ceramic art portfolio.

Opening Reception with Artists: Saturday, February 3, 3:00 – 5:00 PM
Panel Discussion: Ceramic Collecting for the New Generation,   Sunday February 4, 2:00 PM 

The exhibit, opening reception and panel discussion are free and open to the public but kindly RSVP for the panel discussion.

LACOSTE GALLERY
25 Main Street Concord,
MA 01742 978-369-0278
Email: info@lacostegallery.com
Web: www.lacostegallery.com 

–Anita Harris

Anita M.Harris is a writer, photographer, communications consultant and art lover based in Cambridge, MA.
New Cambridge Observer is a publication of the Harris Communications Group, a PR and content marketing firm, also in Cambridge.